

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 June 2018 (28.06.2018)



(10) International Publication Number
WO 2018/115017 A2

(51) International Patent Classification:
C07K 16/22 (2006.01)

(21) International Application Number:
PCT/EP2017/083650

(22) International Filing Date:
19 December 2017 (19.12.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1621635.0 19 December 2016 (19.12.2016) GB

(71) Applicant: **UCB BIOPHARMA SPRL** [BE/BE]; 60, Allée de la Recherche, 1070 Brussels (BE).

(72) Inventors: **DEDI, Neesha**; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **TWOMEY, Breda**; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **WRIGHT, Michael John**; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1

3WE (GB). **DAVIES, Gareth**; c/o IPD, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **MC MILLAN, David James**; c/o IP Department, UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; c/o UCB Celltech, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODY




Figure 2

(57) Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*